{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:26Z","timestamp":1791318926443,"version":"4.3.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jconrel.2011.05.027","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T00:09:39Z","timestamp":1307923779000},"page":"233-240","source":"Crossref","is-referenced-by-count":51,"title":["PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis"],"prefix":"10.1016","volume":"154","author":[{"given":"Ruchi","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.","family":"Proost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alie","family":"de Jager-Krikken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Poelstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2011.05.027_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0010","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/hep.20476","article-title":"Stellate cells: a moving target in hepatic fibrogenesis","volume":"40","author":"Friedman","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-5926-6-7","article-title":"Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options","volume":"6","author":"Gressner","year":"2007","journal-title":"Comp. Hepatol."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","article-title":"Current and future anti-fibrotic therapies for chronic liver disease","volume":"12","author":"Rockey","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0035","first-page":"275","article-title":"Gamma-interferon: physiology and speculation on its role in medicine","volume":"6","author":"Bonnem","year":"1987","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of interferon-gamma","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.21561","article-title":"Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis","volume":"45","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/jir.1988.8.573","article-title":"Pharmacokinetics of recombinant murine interferon-gamma in mice","volume":"8","author":"Rutenfranz","year":"1988","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jps.10007","article-title":"Interferon-gamma therapy: evaluation of routes of administration and delivery systems","volume":"91","author":"Younes","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/hep.510230538","article-title":"Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis","volume":"23","author":"Baroni","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0070","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.21419","article-title":"STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity","volume":"44","author":"Jeong","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/07388550701503410","article-title":"Novel delivery systems for interferons","volume":"27","author":"Hamidi","year":"2007","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-5710(98)00039-5","article-title":"PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques","volume":"68","author":"Francis","year":"1998","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/14728210902907847","article-title":"Emerging PEGylated drugs","volume":"14","author":"Kang","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0095","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0100","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","article-title":"Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data","volume":"39","author":"Camma","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-1759(96)00162-7","article-title":"A nitric oxide production bioassay for interferon-gamma","volume":"198","author":"Kim","year":"1996","journal-title":"J. Immunol. Meth."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-011-0430-9","article-title":"increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the rho-kinase inhibitor Y27632","author":"van Beuge","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0120","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3109\/00365529609036901","article-title":"Animal models of liver fibrosis","volume":"31","author":"Wu","year":"1996","journal-title":"Scand. J. Gastroenterol."},{"issue":"119\u201354","key":"10.1016\/j.jconrel.2011.05.027_bb0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-540-71329-6_7","article-title":"Cell type-specific signaling in response to interferon-gamma","volume":"316","author":"van Boxel-Dezaire","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0130","doi-asserted-by":"crossref","first-page":"tr8","DOI":"10.1126\/stke.2602004tr8","article-title":"The Jak\u2013STAT pathway stimulated by interferon gamma","volume":"2004","author":"Horvath","year":"2004","journal-title":"Sci. STKE"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(00)80468-9","article-title":"Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1","volume":"8","author":"Muhlethaler-Mottet","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev.iy.11.040193.003035","article-title":"The molecular cell biology of interferon-gamma and its receptor","volume":"11","author":"Farrar","year":"1993","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0145","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/14712598.6.10.1051","article-title":"Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis","volume":"6","author":"Bouros","year":"2006","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0150","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1046\/j.1523-1755.1999.00775.x","article-title":"Interferon-gamma inhibits experimental renal fibrosis","volume":"56","author":"Oldroyd","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0155","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1023\/A:1016063109373","article-title":"Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres","volume":"13","author":"Cleland","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2004.10.020","article-title":"Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer","volume":"102","author":"Gu","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.05.027_bb0165","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1006\/bbrc.2001.5896","article-title":"Penicillin conjugates to interferon-gamma and reduces its activity: a novel drug-cytokine interaction","volume":"288","author":"Brooks","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2011.05.027_bb0170","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1365-2249.2003.02069.x","article-title":"Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, IL-1beta, IL-4 and IL-13 but selectively reduces IFN-gamma activity","volume":"131","author":"Brooks","year":"2003","journal-title":"Clin. Exp. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911003865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911003865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T03:22:17Z","timestamp":1543720937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365911003865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0168365911003865"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2011.05.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}